Roche posts ‘impressive’ TIGIT combo lung cancer data, but trial deaths weigh down shares
Roche posts ‘impressive’ TIGIT combo lung cancer data, but trial [...]
Novartis poaches Roche’s neuro and rare disease R&D lead, replacing Shanker
Novartis poaches Roche’s neuro and rare disease R&D lead, replacing [...]
Albireo CMO Horn is out the door 5 months after US, EU approvals of rare liver disease drug
Albireo CMO Horn is out the door 5 months after [...]
Nanomedicine shrinks vascular lesions in mice and could pave path to new treatments
Nanomedicine shrinks vascular lesions in mice and could pave path [...]
ASH: 2 years in, the survival data on J&J’s rival to Bristol Myers’ BCMA cell therapy are still growing
ASH: 2 years in, the survival data on J&J’s rival [...]
K36 emerges with $30M to bankroll multiple myeloma drug in-licensed from Novartis
K36 emerges with $30M to bankroll multiple myeloma drug in-licensed [...]
Totus tots up $40M in series A funding to go after competitive cancer space
Totus tots up $40M in series A funding to go [...]
Novartis works on pan-coronavirus pill, eyes 2022 human testing
Novartis works on pan-coronavirus pill, eyes 2022 human testing badams [...]
Science, talent, money: Eir raises $138M VC fund to fill gap in Nordic life science scene
Science, talent, money: Eir raises $138M VC fund to fill [...]
Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trial
Fresh from $316M raise, Sotio inks Merck deal for Keytruda [...]